ClinicalTrials.gg
RecruitingNCT05890183Updated Aug 4, 2026

Improving Cognition Through Telehealth Aerobic Exercise and Cognitive Training After a First Schizophrenia Episode

An interventional study of Cognitive training and Aerobic Exercise Program in Schizophrenia, Schizophreniform Disorder and Schizoaffective Disorder, sponsored by University of California, Los Angeles. Recruiting at 1 site in United States. Open to participants aged 18 Years to 45 Years. Per ClinicalTrials.gov, last updated 2026-08-04.

Sponsored by University of California, Los Angeles · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started May 2023; still recruiting 3 years 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
100
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 27 studies in Schizophrenia by University of California, Los Angeles — 3 open to participants now, 3 under way, none of them phase 3. Schizophrenia · University of California, Los Angeles.

Planned enrollment
7th of 27
100 · median 61
Started
2023
with 1 other
No phase
12 of 27
2 open now
Registered
25th of 27
by date

Among the 27 studies in Schizophrenia by University of California, Los Angeles, this one is the 7th largest by planned enrollment, is one of 2 that started in 2023, is one of 12 with no phase, and was the 25th registered.

Schizophrenia

3,574 studies on the registry are indexed under Schizophrenia; 494 are open to participants now.

Browse Schizophrenia studies →

Open to participants now

3 of the 27 studies in Schizophrenia by University of California, Los Angeles are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Where they have run

Who these studies take

Of the 333 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 258 (77%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.

This study: 18 Years to 45 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 27 studies in Schizophrenia by University of California, Los Angeles, or all of them as a file.
02

Study summary

The participants in the study will receive psychiatric treatment at the UCLA Aftercare Research Program. All participants in this 12-month RCT will receive cognitive training. Half of the patients will also be randomly assigned to the aerobic exercise and strength training condition, and the other half will be randomly assigned to the Healthy Living Group condition. The primary outcome measures are improvement in cognition and level of engagement in the in-group and at-home exercise sessions. Increases in the level of the patient's serum brain-derived neurotropic factor (specifically Mature BDNF) which causes greater brain neuroplasticity and is indicator of engagement in aerobic exercise, will be measured early in the treatment phase in order to confirm engagement of this target. In order to demonstrate the feasibility and portability of this intervention outside of academic research programs, the interventions will be provided via videoconferencing. The proposed study will incorporate additional methods to maximize participation in the exercise condition, including the use of the Moderated Online Social Therapy (MOST) platform to enhance motivation for treatment based on Self-Determination Theory principles, and a "bridging" group to help the participants generalize gains to everyday functioning. In addition, the exercise group participants will receive personally tailored text reminders to exercise.

Read the detailed description

This R01 confirmatory efficacy clinical trial application involves telehealth delivery of a treatment approach to improving core cognitive deficits in schizophrenia, using an experimental therapeutic design that NIMH has advocated. This telehealth intervention approach combines neurotrophin-releasing aerobic exercise training with neuroplasticity-based cognitive training to enhance the impact of cognitive training on cognition. Telehealth cognitive training and telehealth physical exercise training address the NIMH strategic research priorities for creating innovative interventions that can be "disseminated broadly" and "readily taught to the existing workforce with minimal cost." Cognitive training and physical exercise have each been shown separately to improve cognitive deficits in schizophrenia to some degree, and previous research has shown that, when combined, show promise of improving cognition and work/school functioning more than either treatment alone. Preliminary studies, comparing the combined treatment with cognitive training without aerobic exercise, found evidence of brain-derived neurotrophic factor (BDNF) target engagement, differential improvement in cognition, and prediction of later cognitive outcome from initial BDNF gain. The portability of the proposed intervention outside of academic research programs will be demonstrated by providing the interventions via videoconferencing. The proposed study will incorporate additional methods, such as Fitbit wrist-worn fitness trackers, web-based motivational support, and personalized text messages to encourage motivation and to maximize participation in the exercise condition. Mature BDNF will serve as the primary target and cognition will serve as the primary outcome. It is hypothesized that the increases in Mature BDNF associated with regular aerobic exercise provide a platform which allows neuroplasticity-based cognitive training to enhance cognition more quickly than is typically observed in studies of cognitive training alone. It is hypothesized that combining aerobic exercise with cognitive training will produce larger cognitive improvements, relative to cognitive training without exercise, with all interventions conducted remotely via videoconferencing. Further, it is hypothesized that a greater proportion of exercise sessions completed will be associated with greater cognitive improvement. The research will also test whether intrinsic motivation at baseline and increases in intrinsic motivation over time predict the extent of participation in the telehealth physical exercise program. Cognitive deficits in persons with schizophrenia are a major influence on their everyday functioning in the community. The study targets the period shortly after a first episode of schizophrenia to maximize the generalization of cognitive improvement to real-world functional outcome, before chronic disability is established. This telehealth cognitive training plus aerobic exercise clinical trial has the potential to test a hypothesized mechanism of action and to make a meaningful difference in the lives of individuals with severe mental illness.

03

Conditions studied

  • Schizophrenia
  • Schizophreniform Disorder
  • Schizoaffective Disorder

Keywords

  • First-Episode Schizophrenia
  • Cognitive Remediation
  • Physical Exercise
  • Brain Derived Neurotrophic Factor
  • Telehealth Intervention
  • Moderated Online Social Therapy (MOST)
  • Motivational Text Messaging Program (Chorus)
04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. a first episode of a psychotic illness that began within the past three years;
  2. a diagnosis by of schizophrenia, schizoaffective disorder, or schizophreniform disorder;
  3. age 18 to 45 years of age;
  4. sufficient acculturation and fluency in the English language to avoid invalidating research measures; and
  5. residence likely to be within commuting distance of the UCLA Aftercare Research Program.

Exclusion criteria

Exclusion Criteria:

  1. premorbid IQ less than 70;
  2. evidence of a known neurological disorder (e.g., epilepsy) or significant head injury;
  3. evidence of moderate or severe substance use disorder within the six months prior to the first episode or evidence of a substance-induced psychosis.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
100 participants (estimated)

Study arms

  • Experimental
    Randomization to Combined Cognitive Training and Exercise (CT&E)

    The primary interventions for this arm of the protocol are Cognitive Training and Exercise sessions. The Cognitive Training will be conducted in a group format using Zoom videoconferencing, with participants logging into their individual Posit Science cognitive training accounts. The Aerobic Exercise Program will consist of a physical exercise intervention of 150 minutes/week of moderate aerobic activity, over 4 days, including two group sessions (45 min duration) and two individual sessions (30 min duration in the heart rate zone), for 6 months. After the first 6 months, the group sessions will be once a week with the continuing goal of 150 minutes/week of moderate exercise.

    Behavioral: Cognitive training · Behavioral: Aerobic Exercise Program · Behavioral: Moderated Online Social Therapy (MOST) · Behavioral: Chorus Participatory Text Messaging Program

  • Active comparator
    Cognitive Training and Healthy Living Group (CT&HLG)

    The primary interventions for this arm of the protocol are Cognitive Training and the Healthy Living Group. The Cognitive Training will be conducted in a group format using Zoom videoconferencing, with participants logging into their individual Posit Science cognitive training accounts. The participants in this arm will also participate in a Healthy Living Group, which is a didactic, educational and interactive group that is designed to offer very useful information and discussion of topics that are relevant to a healthy lifestyle. It includes manualized modules devoted to wellness, nutrition, insight, recovery, independent living, social skills, and hobbies. It meets 2 times/week for 6 months and then once a week for the next 6 months.

    Behavioral: Cognitive training · Behavioral: Moderated Online Social Therapy (MOST) · Behavioral: Healthy Living Group (HLG)

Interventions

  • BehavioralCognitive training

    This systematic cognitive training program will be delivered by telehealth sessions in which each patient logs into their Posit Science account and joins a Zoom videoconference with 4-8 other patients and two cognitive coaches. The first 12 weeks focus on neurocognitive training and the second 12 weeks focus on social cognitive training. Patients have two CT sessions on each of two days each week to complete 4 hours/week of computerized cognitive training for the first 6 months. Thus, each patient will receive 48 hours of neurocognitive training and 48 hours of social cognitive training in the first 6 months. In the second 6 months, the number of hours per week is trimmed to half the dosage.

  • BehavioralAerobic Exercise Program

    The Aerobic Exercise Program group sessions will be conducted by Zoom videoconferencing. The group exercise training sessions are a combination of moderate intensity aerobic conditioning (1-min intervals) and moderate to high intensity strength and callisthenic conditioning (1-min intervals). The exercise dosage goal is 150 minutes/week of moderate aerobic activity, over 4 days, including for the first 6 months two group sessions (45 min duration) and two individual sessions personalized to the patient's choice of exercise (30 min duration) in the target heart rate zone. After the first 6 months, the group exercise sessions are once a week but the goal remains 150 minutes/week of moderate exercise.

  • BehavioralModerated Online Social Therapy (MOST)

    MOST combines: (1) evidence-based, interactive, user-directed web-based interventions; (2) secure and supportive peer-to-peer web-based social networking; (3) moderator support; and (4) on-demand web chat with registered clinicians. A Motivation Track on the MOST platform will be used to encourage intrinsic motivation for self-improvement for both groups and, for the CT\&E group, involvement in our exercise program.

  • BehavioralChorus Participatory Text Messaging Program

    The Chorus text messaging program is a web-based application that allows clinicians to create a broad range of automated SMS text messages and interactive voice responses using a simple, accessible graphical user interface. It will target encouragement to exercise and social feedback on completed exercise in the CT\&E group.

  • BehavioralHealthy Living Group (HLG)

    The Healthy Living Group (HLG) meets two sessions/week to discuss wellness, nutrition, insight, recovery, independent living, social skills, and hobbies for the first 6 months and then one session/week for the next 6 months.

06

What researchers measure

Primary outcomes

  1. Change in Serum Mature BDNF

    A brain neurotrophic factor that stimulates synaptic plasticity and neurogenesis

    Time frame: Outcome is change from baseline to 2 weeks.

  2. Change in Serum Mature BDNF

    A brain neurotrophic factor that stimulates synaptic plasticity and neurogenesis

    Time frame: Outcome is change from baseline to 3 months.

  3. Change in Overall Composite T-score from the MATRICS Consensus Cognitive Battery (MCCB)

    A summary of overall cognitive performance on the MATRICS Consensus Cognitive Battery

    Time frame: Outcome is change from baseline to 3 months.

  4. Change in Overall Composite T-score from the MATRICS Consensus Cognitive Battery (MCCB)

    A summary of overall cognitive performance on the MATRICS Consensus Cognitive Battery

    Time frame: Outcome is change from baseline to 6 months.

  5. Change in Intrinsic Motivation Inventory for Schizophrenia Research (IMI-SR)

    21 items that assess motivational experiences in three domains: Interest/enjoyment, perceived choice, and value/usefulness.

    Time frame: Outcome is change from baseline to 3 months.

  6. Change in Intrinsic Motivation Inventory for Schizophrenia Research (IMI-SR)

    21 items that assess motivational experiences in three domains: Interest/enjoyment, perceived choice, and value/usefulness.

    Time frame: Outcome is change from baseline to 6 months.

  7. Attendance at Exercise Sessions for First Three Months

    Proportion of group sessions completed by the participants in the exercise group

    Time frame: First Three Months After Baseline

  8. Attendance at Exercise Sessions for First Six Months

    Proportion of group sessions completed by the participants in the exercise group

    Time frame: First Six Months After Baseline

07

Study locations

1 of 1 sites recruiting
  • UCLA Aftercare Research Program
    Los Angeles, California 90095-6968, United States
    Recruiting
    • Keith H Nuechterlein, PhD · Contactkeithn@ucla.edu · (310) 206-3142
    • Kenneth L Subotnik, PhD · Contactksubotnik@mednet.ucla.edu · 3108250334
    • Keith H. Nuechterlein, PhD · Principal investigator
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2023 (actual). Primary completion is estimated for May 2028, 60 months after the start.

Of 763 non-industry interventional studies with no phase under Schizophrenia, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 56. This study's planned 60 months is above that.

Counting every sponsor, half of 776 studies reached it within 32 months; a quarter within 16 and three quarters within 56.

How these figures are worked out, and which studies are left out of them.

Registered
May 9, 2023
First posted
Jun 6, 2023
StartActual
May 23, 2023
Primary completionEst.
May 31, 2028
CompletionEst.
May 31, 2028
Last update
Aug 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 4, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05890183
Responsible party
Keith Nuechterlein, Ph.D. (Principal Investigator, University of California, Los Angeles) — Principal investigator
First posted
Jun 6, 2023
Start date
May 23, 2023
Primary completion
May 31, 2028 (estimated)
Completion
May 31, 2028 (estimated)
Last update
Aug 4, 2026

Study contacts

Danielle Denenny, PhD
Contact
Ddenenny@mednet.ucla.edu
(323) 475-8252
Alma Munguia
Contact
AMunguia@mednet.ucla.edu
(310) 206-3142
Keith H Nuechterlein, PhD
principal investigator · University of California, Los Angeles

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion